Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Goodwill & Intangibles (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Goodwill & Intangibles for 12 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Goodwill & Intangibles fell 9.31% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 9.31%, and an annual FY2024 reading of $1.5 million, down 8.7% over the prior year.
  • Goodwill & Intangibles was $1.4 million for Q3 2025 at CytomX Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $2.1 million in Q1 2021 and bottomed at $1.4 million in Q3 2025.
  • Average Goodwill & Intangibles over 5 years is $1.8 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Goodwill & Intangibles decreased 6.56% in 2021, then fell 9.31% in 2025.
  • Year by year, Goodwill & Intangibles stood at $2.0 million in 2021, then fell by 7.41% to $1.8 million in 2022, then fell by 8.0% to $1.7 million in 2023, then decreased by 8.7% to $1.5 million in 2024, then fell by 7.11% to $1.4 million in 2025.
  • Business Quant data shows Goodwill & Intangibles for CTMX at $1.4 million in Q3 2025, $1.5 million in Q2 2025, and $1.5 million in Q1 2025.